Home>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA Methyltransferase>>CM-579 trihydrochloride

CM-579 trihydrochloride

Catalog No.GC35714

CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.

Products are for research use only. Not for human use. We do not sell to patients.

CM-579 trihydrochloride Chemical Structure

Size Price Stock Qty
10mM (in 1mL DMSO)
$307.00
In stock
5mg
$232.00
In stock
10mg
$362.00
In stock
50mg
$1,020.00
In stock
100mg
$1,391.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells[1]. DNA Methyltransferase|32 nM (IC50)|DNMT1|1.5 nM (Kd)|DNMT3A|92 nM (IC50)|DNMT3B|1000 nM (IC50)|G9a|16 nM (IC50)

The Kd of CM-579 for DNMT1 is 1.5 nM, CM-579 also inhibits DNMT3A and DNMT3B, with IC50s of 92 nM and 1000 nM, respectively[1].

[1]. San JosÉ-EnÉriz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.

Reviews

Review for CM-579 trihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CM-579 trihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.